Drugs / M5A
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05245786 | Aug 2022 → Nov 2026 expected | rectal carcinoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT03993327 | Jul 2020 → Jun 2024 | colorectal carcinoma, metastasis from malignant tumor of colon | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01205022 | Apr 2011 → Jan 2014 | rectal cancer | City of Hope Medical Center | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02293954 | Nov 2015 → Mar 2022 overdue | breast cancer, colon carcinoma, extrahepatic bile duct carcinoma, gallbladder cancer +5 | City of Hope Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M5A | “yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A” NCT01205022 ↗ |
| Modality | Monoclonal antibody | “anti-CEA monoclonal antibody M5A” NCT01205022 ↗ |
| Route | Intravenous | “Patients also receive yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A IV over 25 minutes” NCT01205022 ↗ |